BIOGRAPHICAL SKETCH
NAME:
Jan A. Nolta, Ph.D.
eRA COMMONS USER NAME:
POSITION TITLE:
Jnolta
Professor, Director of the Stem Cell Program,
University of California, Davis
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
California State University Sacramento, CA
University of Southern California, L.A., CA
Childrens Hospital of Los Angeles, CA
DEGREE
B.S.B.S.
Ph.D.
Ph.D.
Post-Doc
Postdoc
YEAR(s)
1984
1984
1984
1990-94
1994
1994-97
1996
FIELD OF STUDY
Biology
Biology
Biology
Molecular
Microbiology
Microbiology
Stem
Gene
Post-Doc
Cell
Therapy
Gene 1996
Therapy
Professional Experience and Duties:
Professor, Director of the Stem Cell Program and Institute for Regenerative Cures, Scientific Director-GMP Facility for
> and Gene Therapy, UC Davis School of Medicine, Department of Internal Medicine, Division of Hematology/
Cell
Oncology. November 1, 2006 - present.
Associate Professor of Medicine & Pathology/Immunology, Washington University School of Medicine, Div. Oncology,
- Stem Cell Program (May 2002 –December 2006). Tenure granted September 2002.
Scientific Director, Washington University Good Manufacturing Practice (GMP) Facility (December 2002 to Feb 07).
Washington Univ. Animal Studies Committee (2003- 2006) Member, CHLA Animal Care Committee (1997 – 2002)
Assistant Professor of Pediatrics, Univ. of Southern California School of Medicine, L.A., CA (June 1997- May 2002)
Member, Norris Comprehensive Cancer Center, Developmental Therapeutics & Clin. Trials Research program (1998-02)
Chair, Institutional Biosafety Committee, Childrens Hospital of Los Angeles (May 2000 – May 2002)
Graduate Faculty, USC School of Medicine, Department of Developmental Biology (July 1997-March 2002)
Postdoctoral Fellow, John Connell Gene Therapy Foundation –Donald Kohn’s laboratory, CHLA (1994-1997)
Graduate Student, University of Southern California School of Medicine, Dept. of Molecular Microbiology (1990 – 1994)
Research Specialist II-IV, Dept. Research Immunology/ BMT, Childrens Hospital Los Angeles, L.A., CA (1987-1990)
Hematology Laboratory Technician/ Night Shift Supervisor, UC Davis Medical Center (1983-87)
Honors:
Honors at Entrance, California State University; Dean's Honor List, CSUS, UC Davis, USC
Lifetime Member California Scholarship Foundation (1980), BA Scholarship (‘83), Golden Key Honor Society (‘84)
American Society of Hematology Travel Grants (1988-1995), NRSA Training Grant (1991 - 1993)
Dean's Honor List, USC Graduate School (4.0 GPA; 1990 - 1994)
International Society of Hematology New Investigator Award (1996)
Research Career and Development Award, CHLA Research Institute (1996)
James Shannon Directors Award, NIH NIDDK (1997)
Huntington’s Disease Society of America Distinguished Leadership Award (2008)
California State University, Sacramento Distinguished Service Award (2009)
Deans Award for Team Excellence (2011)
Activities:
Member: American Society of Hematology, AAAS, International Society of Experimental Hematology; American
Society for Gene Therapy, International Society for Stem Cell Research (ISSCR)
International Society for Hematology and Graft Engineering (ISHAGE) Gene Therapy Committee (1998-99)
Moderator/ reviewer/session chair at the Annual Meeting of the American Society for Hematology (1997 – 2009)
P01 review panels & site visits, NHLBI, NCI, NIDDK 1999-2007, Chair NIDDK, NHLBI stem cell reviews 2003,
Reviewer, Italian Telethon Grants Administration Program, 1998 – present, NIH NCRR COBRE grants 2008
US Army BCA grant review sessions, 2000, 2001.Chair: IBC Gene Therapy Workshop, Lake Tahoe, CA, 1999
External Advisory Boards: Univ. Minnesota Stem Cell PPG (2000-2002) & Seattle CF Gene Therapy Program, 2000
Ad-hoc member, HEM-1 and HEM-2 Study Sections, NIH (1998- 2003)
International Society of Experimental Hematology (ISEH) Nominating Committee, 2001-4. Chair: 2003-4.
American Society of Gene and Cell Therapy, Hematopoietic Therapy committee, 2003-2006. Chair, 2004-2006,
Chair, ASGT embryonic stem cell and tissue engineering committee, 2006-2009, nominating committee 2009-.
Editorial Board, Human Gene Therapy, 2001-2009, Editorial Board, Experimental Hematology, 2000 – present
Section Editor, Leukemia: stem cells, 2001 – 2002, Gene Therapy 2000-2006. Editorial Board,1999-2005.
Editorial Board, Blood, September 2002 – 2008, Editorial Board, Molecular Therapy, 2003- 2006.
Full Member, Hematology B Study Section, National Institutes of Health, May 2003-June 2007. Ad Hoc 2008Chair, New York Stem Cell Research Program (NYSTEM) Major Shared Facilities Panel, 2008 - 2010
Member, Huntington’s disease Communications Group of the Huntington’s Study group, 2008-present
Member, International Society of Cell Therapy Commercialization Committee, 2011-present
NHLBI Production Assistance for Cellular Therapies (PACT) External Expert Panel Member, 2010-present
Gene T
Associate Editor, Stem Cells, February 2008 – December 2011
Editor, Stem Cells, January 2012 - 2016
Publications (Selected, of over 100 peer-reviewed manuscripts)
1. Nolta JA, Kohn DB. Expression of hu GC in murine LTBMC after retroviral vector-mediated transfer. Blood 75:787-97, 1990.
2. Ozkaynak M, Nolta JA, Parkman R. Purging of rhabdomyosarcoma cells using 4-HC. Cancer Research 50:1455-58,1990.
3. Nolta JA, Kohn DB. Comparison of the effects of growth factors on retroviral vector-mediated gene transfer and the proliferative
status of human hematopoietic progenitor cells. Human Gene Therapy 1(3):257-268, 1990.
4. Lenarsky C, Weinberg K, Nolta J, Annett G, Kohn D, Parkman R. Autologous bone marrow transplantation with 4-HC purged
marrows for children with acute non-lymphoblastic leukemia in 2nd remission. Bone Marrow Transplantation 6:425-429, 1990.
5. Weinthal J, Nolta JA, Yu X-J, Lilley J, Uribe L, Kohn D. Expression of human GC following retroviral vector-mediated
transduction of murine hematopoietic stem cells. Bone Marrow Transplantation 8:403-412, 1991.
6. Kohn D, Nolta J, Yu X-J, Lilley J, Crooks G. Towards gene therapy for Gaucher disease.Human Gene Therapy 2:101-105, 1991.
7. Tishler DM, Weinberg KI, Sender LS, Nolta JA, Raffel C. Multidrug resistance gene expression in pediatric primitive
neuroectodermal tumors of the central nervous system. Journal of Neurosurgery 76:507-512, 1992.
8. Nolta JA, Crooks GM, Overell RW, and Kohn DB. Retroviral vector-mediated gene transfer into primitive human hematopoietic
progenitor cells: effects of mast cell growth factor (MGF) combined with other cytokines. Expt. Hematology 20:1065-1071, 1992.
9. Nolta JA, Yu XJ, Kohn DB. Retroviral-mediated transfer of the huGC gene into Gaucher BM. J. Clin. Invest. 90:342-348, 1992.
10. Nolta JA, Hanley M, Kohn DB. Sustained human hematopoiesis in immunodeficient mice by co-transplantation of marrow
stroma expressing human IL-3: Analysis of gene transduction of long-lived progenitors. Blood 83:3041-3051, 1994.
11. Nolta JA, Smogorzewska EM, Kohn DB. Analysis of optimal conditions for retroviral-mediated transduction of primitive human
hematopoietic stem cells. Blood 86; 101 - 110, 1994.
12. Hanley ME, Nolta JA, Parkman R, and Kohn DB. Umbilical cord blood cell transduction by retroviral vectors: preclinical studies
to optimize gene transfer. Blood Cells 20; 539 - 546, 1994.
13. Wells S, Kohn D, Nolta JA. Stromal support optimizes transduction of Gaucher LTCIC. Gene Therapy 2, 512-520, 1994.
14. Kohn DB, Weinberg KI, Nolta JA., Parkman R. et al. Engraftment of gene-modified cells from Umbilical Cord Blood in
neonates with ADA deficiency. Nature Medicine 1; 1017-1023, 1995.
15. Nolta JA, Dao MA, and Kohn DB. Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis
after engraftment in immune deficient mice. Proc. Natl. Acad. Sci. USA 93; 2414-2419, 1996.
16. Nolta JA, Kohn DB. Hematopoietic stem cells for gene therapy. In Stem Cells, Ed: C. Potten, Academic Press, pp. 447-61, 1996.
17. Dao MA and Nolta JA. Inclusion of IL-3 During Retroviral-Mediated Transduction on Stromal Support Does Not Increase
the Extent of Gene Transfer Into Long-Term Engrafting Human stem cells. Cell. Mol. Ther. 3:81-90, 1997.
18. Dao MA, Hannum CH, and Nolta JA. FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long-term
hematopoiesis in immune deficient mice following ex-vivo retroviral - mediated transduction. Blood 89:446-456, 1997.
19. Dao MA, Yu XJ, and Nolta JA. Clonal diversity of retroviral vector - marked primitive human hematopoietic progenitors
recovered from long-term engrafted immune deficient mice. Expt. Hematol. 25:1357-1366, 1997.
20. Dao MA, Pepper, KA, and Nolta JA. Human cytokine production from engineered stromal cells influences hematopoietic
development from co-transplanted human CD34+ progenitors in immune deficient mice. Stem Cells 15:443-453, 1997.
21. Dao MA, Hashino K, Kato I, and Nolta JA. Adhesion to fibronectin maintains regenerative capacity during ex-vivo culture and
transduction of human hematopoietic stem and progenitor cells. Blood 92: 4612-4621, 1998.
22. Dao M, Nolta JA. Hematopoietic stem cells as targets for Gene Therapy: Cancer Research, Therapy and Control 7:19-25, 1998.
23. Dunbar CE, Kohn DB, Schiffmann R, Barton NW, Nolta JA, Esplin J, Pensiero M, Emmons RVB, Leitman S, Krebs CB, Carter
CC, Brady RO, and Karlsson S. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher
disease: in vivo detection of transduced cells without myeloablation. Human Gene Therapy 9: 2692-2640, 1998.
24. Dao MA, Shah AJ, Smogorzewska EM, Crooks GC, and Nolta JA. Comparison of human hematopoietic progenitor content and
retroviral marking in immune deficient mice transplanted with CD34+ vs. CD34+/38- cells. Blood 91(3): 1243-1255, 1998.
25. Kohn DB, Hershfeld MS, Nolta JA, Parkman R et al. Selective accumulation of T cells containing a normal ADA gene four years
after transduced autologous UCB CD34+ cell BMT in ADA-deficient SCID neonates. Nature Medicine 4:775-780, 1998.
26. Dao M, Taylor N, Nolta J. Reduction in levels of the CDK inhibitor p27 kip-1 coupled with TGF neutralization induces cell cycle
entry & increases retroviral transduction of primitive human hematopoietic cells. Proc Natl Acad Sci USA 95:13006-13011, 1998.
27. Epstein A, Liu M, Nolta JA, and Durden DL. Cbl functions downstream of SRC kinases in FcRI signaling in primary human
macrophages. Journal of Leukocyte Biology, 65: 1-12, 1999.
28. Dao MA and Nolta JA. Molecular control of cell cycle progression in primary human hematopoietic stem cells: Methods to
increase levels of retroviral - mediated transduction. Leukemia 13:1473-1480, 1999.
29. Arakawa-Hoyt J, MA Dao, F Thiemann, KI Weinberg, GM Crooks, and Nolta JA. The number and generative capacity of human
B cell progenitors is higher in umbilical cord blood than in bone marrow. Bone Marrow Transplantation 24: 1167-1176, 1999.
30. Dao MA, Tsark E, Nolta JA. Animal xenograft models for evaluation of gene transfer into human hematopoietic stem cells.
Current Opinion in Molecular Therapeutics 1:553-557, 1999.
31. Parkman R, Weinberg K, Crooks G, Nolta J, Kohn D. Gene therapy for ADA deficiency. Ann. Rev. Med. 51:33-47, 2000.
32. Evans M, Jordan C, Nolta, JA, Wivel N et al. Clinical Infection Control in Gene Therapy. Infection Control 21: 659 – 673, 2000.
33. Tsark E, Dao MA, Weinberg KI, and Nolta JA. Interleukin 7 (IL-7) enhances the responsiveness of human T cells that develop in
the bone marrow of athymic mice. Journal of Immunology 166: 170 – 181, 2001.
34. Wang X, Dao MA, Kuo I and Nolta JA. Phenotypic comparison of extrathymic human bone marrow-derived T cells with thymicselected T cells recovered from different tissues. Clinical Immunology, 100 (3), 339 - 348, 2001.
35. Nolta JA, Thiemann F, Arakawa J, Dao M, Barsky, Moore KA, Lemischka I, Crooks GM. The AFT024 stromal cell line supports
long-term ex vivo maintenance of engrafting multipotent human hematopoietic progenitors. Leukemia 16: 352-361, 2002.
36. Nolta JA. Cell - Based Therapy: will it replace pharmaceuticals in some cases? Current Drugs 4:212-218, 2002
37. Dao MA., Hwa J and Nolta JA. Molecular mechanism of transforming growth factor beta-mediated cell-cycle modulation in
primary human CD34(+) progenitors. Blood. Jan 15; 99 (2):499-506, 2002.
38. Gussoni E, Meyerrose TE, Nolta JA, Weinberg KA, Kunkel LM, et al. Long-term persistence of donor nuclei in a Duchenne
muscular dystrophy patient receiving bone marrow transplantation. Journal of Clinical Investigation Sept.; 110(6):807-14, 2002.
39. Dao MA, Arevalo JA, and Nolta JA. Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity
for secondary reconstitution. Blood Jan 1; 101(1); 112-118, 2003.
40. Wu G, Nolta JA, Starnes V, and Cramer D. Migration of mesenchymal stem cells to heart allografts during chronic rejection.
Transplantation Mar 15; 75(5): 679-685, 2003.
41. Bauer G, Nolta JA, Walker JE, Devine S, DiPersio J. Design and construction of a GMP facility for cellular and gene therapy in
an academic center-implementing new regulatory requirements. Stem Cell and Cellular Therapy 1:54-61, 2003.
42. Schmidt M, Carbonaro D, Speckmann C, Bohnsack J, Nolta JA, Kohn D, von Kalle C. Clonality Analysis after retroviral–
mediated gene transfer to cord blood CD34+ cells of an ADA-deficient SCID infant. Nature Medicine, Apr1; 9(4); 463-68, 2003.
43. Wang X, Ge S, McNamara G, Hao QL, Crooks GM, and Nolta JA. Albumin-expressing hepatocyte-like cells develop in the
livers of immune-deficient mice transplanted with highly purified human stem cells. Blood, May 15; 101 (10): 4201-4208, 2003.
44. Kohn DB, Dunbar C, Bodine D, Kiem HP, Candotti F, Tisdale J, Blau CA, Sorrentino B, Nolta J, et al. American Society of
Gene Therapy ad hoc subcommittee on retroviral-mediated gene transfer to stem cells. Mol Ther. Aug;8(2):180-7, 2003
45. Mohamedali A, Moreau-Gaudry F, Richard E, Xia P, Nolta J, Malik P. Self-inactivating lentiviral vectors resist proviral
methylation but do not confer position-independent expression in hematopoietic stem cells. Mol Ther. Aug;10(2):249-59, 2004.
46. J Bonde, D Hess, J Nolta. Recent advances in hematopoietic stem cell biology. Curr Opin Hematol. Nov;11(6):392-8, 2004.
47. D Hess, T Meyerrose, L Wirthlin, M Creer, P Herrbrich, T Craft, Nolta J. Functional characterization of highly purified human
hematopoietic repopulating cells isolated based on aldehyde dehydrogenase activity. Blood, Sept.104:1648-55, 2004.
48. Smith E, Meyerrose T, Kohler T, Nolta JA, Muller R, Bab I, Frenkel B. Leaky ribosomal scanning in mammalian genomes:
significance of histone H4 alternative translation in vivo. Nucleic Acids Res. Mar 01;33(4):1298-308, 2005.
49. Sohara Y, Shimada H, Minkin C, Erdreich-Epstein A, Nolta JA, DeClerck YA. Bone marrow mesenchymal stem cells provide an
alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res. Feb 15; 65: 1129-35, 2005.
50. Hess DA, Wirthlin L, Craft T, Hohm S, Lahey R, Eades WC, Creer MH, Nolta JA. Selection based on CD133 and high aldehyde
dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood, March 1; 107(5):2162-9, 2006.
51. Dao MA and Nolta JA. Cytokine and integrin stimulation synergize to promote higher levels of GATA-2, c-myb, and CD34
protein in primary human hematopoietic progenitors from bone marrow. Blood.109(6):2373-9, Mar 15, 2007.
52. Meyerrose TE, DeUgarte DA, Hofling A, Herrbrich P, Sands MS, Hedrick MA, and Nolta JA. In vivo Distribution of AdiposeDerived Mesenchymal Stem Cells in Novel Xenotransplant Models. Stem Cells.; 25; 220-227, 2007.
53. Partlow KC, Brant J, Chen J, Meyerrose TE, Nolta JA, Caruthers S, Lanza G, and Wickline SA. 19F magnetic resonance imaging
for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J. Jun;21(8):1647-54, 2007.
54. Hess DA, Bonde J, Wirthlin L, Dipersio J, Devine S, Nolta J. Human progenitors rapidly mobilized by AMD3100 repopulate
NOD/SCID mice with increased efficiency compared to G-CSF-mobilized cells. Biol.Blood MarrowTransplnt 13:398-411, 2007.
55. Dao MA, Nolta JA, Creer MH, Verfaillie CM. Biology of umbilical cord blood progenitors in bone marrow niches.
Mar 19. Blood Jul 1;110(1):74-81, 2007.
56. S X. Qiu, C Dan, L-S Ding, S Peng, S-N Chen, N Farnsworth, J Nolta, M Gross, Ping Zhou. A Triterpene Glycoside from Black
cohosh that Inhibits Osteoclastogenesis by Modulating RANKL and TNF Signaling Pathways. Chem Biol. 14:860-9, 2007.
57. B. Nervi, M. Rettig, J. Ritchey, J. Nolta, G. Bauer, J. DiPersio. A new model for GvHD: naïve and ex-vivo activated human T
cells generate consistent engraftment and lethal disease in NOD/SCID/B2M null mice. Exp Hem. Dec;35(12):1823-38, 2007.
58. D. Maxwell, J. Bonde, D. Hess, M. Creer, R. Lahey, D. Piwnica-Worms, and J. Nolta. Fluorophore-conjugated iron oxide
nanoparticle labeling and analysis of engrafting human stem cells. Stem Cells. Feb;26(2):517-24. 2008.
59. D. Hess, T. Craft, L. Wirthlin, W. Eades, M. Creer, M. Sands, J. Nolta. Widespread nonhematopoietic tissue distribution by
transplanted human progenitor cells with high aldehyde dehydrogenase activity. Stem Cells. Mar;26(3):611-20. 2008.
60. G Bauer, M Dao, S Case, P Herrbrich, J Arevalo, T Meyerrose, X Wang, S Csik, D Skelton, D B. Kohn, and J Nolta. In Vivo
Biosafety Model to Assess Risk of Adverse Events from Retroviral and Lentiviral Vectors. Mol Ther. Jul;16(7):1308-15, 2008.
61. T Meyerrose, M Roberts, K Ohlemiller, C Vogler, L Wirthlin, J Nolta, M Sands. Lentiviral-transduced human mesenchymal stem
cells persistently express therapeutic levels of enzyme in a xenotransplant model of human disease. Stem Cells.26:1713-22. 2008.
62. Zhou P, Hohm S, Capoccia B, Link D, and Nolta JA. Immunodeficient mouse models to study human stem-cell mediated repair
of tissue injury. Methods Mol Biol; 430:213-25, 2008.
63. J.Rich, I. Rosova, J. Nolta, T. Myckatyn, L. Sandell, A. McAlinden. Upregulation of Runx2 and Osterix during in vitro
chondrogenesis of human adipose-derived stromal cells. Biochem Biophys Research Com. Jul 18;372(1):230-5. 2008.
64. Rosová I, Dao MA, Capoccia BJ, Link DC, Hess DA, Nolta JA. Hypoxic Preconditioning Results in Increased Motility and
Improved Therapeutic Potential of Human Mesenchymal Stem Cells. Stem Cells. Aug;26(8):2173-82. 2008.
65. Anderson JS, Javien J, Nolta JA, Bauer G. Preintegration HIV-1 Inhibition by a Combination Lentiviral Vector Containing a
Chimeric TRIM5alpha Protein, a CCR5 shRNA, and a TAR Decoy. Mol Ther. Aug 18. [Epub ahead of print]. 2009.
66. Anderson J, Nolta JA, Bauer G. Specific Transduction of HIV-Susceptible Cells for CCR5 Knockdown and Resistance to HIV
Infection: A Novel Method for Targeted Gene Therapy and Intracellular Immunization. J Acquir Immune Defic Syndr. 2009.
67. P. Zhou, L. Wirthlin, J. McGee, G. Annett, and J. Nolta. Contribution of human hematopoietic stem cells to liver repair. Seminars
in Immunopathology Sep;31(3):411-9. Epub 2009 Jun 17.2009.
68. P. Zhou, R. Lahey, S. Hohm, D. Hess, J Nolta. Human progenitor cells with high aldehyde dehydrogenase activity efficiently
engraft into damaged liver in a novel model. Hepatology 49 (6): 1992 – 2000, 2009.
69. Capoccia BJ, Robson DL, Levac KD, Maxwell DJ, Hohm SA, Neelamkavil MJ, Bell GI, Xenocostas A, Link DC, PiwnicaWorms D, Nolta JA, Hess DA. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high
aldehyde dehydrogenase activity. Blood 21 May, 113 ( 21): 5340-5351, 2009.
70. P Zhou, S Gross, J-H Liu, B-Y Yu, LL Feng, JA Nolta, V Sharma, D Piwnica-Worms and SX Qiu. Flavokawain B, the
Hepatotoxic Constituent from Kava Root, Induces GSH-Sensitive Oxidative Stress through Modulation of IKK/NF-κB and
MAPK Signaling Pathways. FASEB J. Dec;24(12):4722-32, 2010.
71. I. Rosová, D. Link, and Nolta J. Small Interfering RNA-Mediated Decreases in c-Met Levels Affect the Differentiation Potential
of Human Mesenchymal Stem Cells and Reduce Their Capacity for Tissue Repair. Tissue Engineering Aug;16(8):2627-39, 2010.
72. Sondergaard CS, Hodonsky CJ, Khait L, Shaw J, Sarkar B, Birla R, Bove E, Nolta J, Si MS. Human Thymus Mesenchymal
Stromal Cells Augment Force Production in Self-Organized Cardiac Tissue. Ann Thorac Surg. Sep; 90(3):796-804, 2010.
73. Chen X, Lingala S, Zern M, Nolta J., Wu J. Epithelial mesenchymal transition and hedgehog signaling activation are associated
with chemoresistance and invasion of hepatoma subpopulations. Journal of Hepatology, Oct;55(4):838-45, 2011.
74. C Sondergaard, D Hess, D Maxwell, I Rosová, D Piwnica-Worms, A Kovacs, L Pedersen, and J Nolta. Human UCB Progenitors
with High ALDH Activity Improve Vascular Density in Acute Myocardial Infarction. J. Translational Medicine. 8:24-9, 2010.
75. Zhou P, Estrada, D, Lingala S, Zern M, Nolta, J, Wu, J. Decellularized Liver Matrix as a Carrier for Transplantation of Human
Fetal and Primary Hepatocytes in Mice. Liver Transplantation; 17(4):418-27. 2010.
76. Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta J. Mesenchymal stem cells for the treatment of neurodegenerative
disease. Regenerative Medicine Nov; 5(6):933-46, 2010.
77. Kambal A, Mitchell G, Cary W, Gruenloh W, Jung Y, Kalomoiris S, Nacey C, McGee J, Lindsey M, Fury B, Bauer
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
G, Nolta JA, Anderson JS. Generation of HIV-1 Resistant and Functional Macrophages From Hematopoietic Stem
Cell-derived Induced Pluripotent Stem Cells. Molecular Therapy Mar; 19(3):584-93, 2011.
Meyerrose T, Olson S, Pontow S, Kalomoiris S, Jung Y, Annett G, Bauer G, Nolta JA. Mesenchymal stem cells for
the sustained in vivo delivery of bioactive factors. Advances in Drug Delivery Reviews 62 (12) 1167-74, 2010.
Gruenloh W, Kambal A, Sondergaard C, McGee J, Nacey C, Olson S, Fierro F, Nolta JA, Characterization and In
Vivo Testing of Mesenchymal Stem Cells Derived From Human Embryonic Stem Cells. Tissue Engineering 17 (11)
1517-25, 2011.
Fierro FA, Kalomoiris S, Nolta JA. Effects on proliferation and differentiation of multipotent mesenchymal stromal
cells over-expressing growth factors for combined gene/cell therapy. Stem Cells 29(11):1727-37, 2011.
Jun-feng Feng, Jing Liu, Xiu-zhen Zhang, Lei Zhang, Ji-yao Jiang, Jan Nolta, Min Zhao. Guided Migration of Neural
Stem Cells Derived from Human Embryonic Stem Cells by an Electric Field. Stem Cells. Feb; 30(2):349-55, 2012.
Y Jung, G Bauer, and J Nolta. Induced pluripotent stem cells and mesenchymal stem cells: progress toward safe
clinical products. Stem Cells. Jan;30(1):42-7, 2012.
Mathews G, Sondergaard C, Jeffreys A, Childs W, Le B, Sahota A, Najibi S, Nolta J, Si MS. Computational Analysis
of Contractility in Engineered Heart Tissue. IEEE Trans Biomed Eng. May; 59(5):1429-35, 2012.
Park SS, Caballero S, Bauer G, Shibata B, Roth A, Fitzgerald PG, Forward KI, Zhou P, McGee J, Telander DG, Grant
MB, Nolta JA. Long-Term Effects of Intravitreal Injection of GMP-Grade Bone-Marrow-Derived CD34+ Cells in
NOD-SCID Mice with Acute Ischemia-Reperfusion Injury. Invest Ophthalmol Vis Sci. Feb 23;53(2):986-94, 2012.
Murphy WJ, Nolta JA. Autoimmune T Cells Lured to a FASL Web of Death by MSCs. Cell Stem Cell. 2012 May
4;10(5):485-7.
Liu J, Koscielska KA, Cao Z, Hulsizer S, Grace N, Mitchell G, Nacey C, Githinji J, McGee J, Garcia-Arocena D,
Hagerman RJ, Nolta J, Pessah I, Hagerman PJ. Signaling defects in iPSC-derived fragile X premutation neurons.
Hum Mol Genet. In press, 2012 May 28.
Walker JE, Chen RX, McGee J, Nacey C, Pollard RB, Abedi M, Bauer G, Nolta JA, Anderson JS. Generation of an
HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination antiHIV lentiviral vector. J Virol. 2012 May;86(10):5719-29, 2012
S Olson, A Kambal, K Pollock, G Mitchell, H Stewart, S Kalomoiris, W Cary, C Nacey, K Pepper, J Nolta.
Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for
reduction of huntingtin. Molecular and Cellular Neuroscience Mar;49(3):271-81, 2012.
S Olson, K Pollock, A Kambal, W Cary, G Mitchell, J Tempkin, H Stewart, J McGee, G Bauer, T Tempkin, V
Wheelock, G Annett, G Dunbar and J Nolta, Genetically Engineered Mesenchymal Stem Cells as a Proposed
Therapeutic for Huntington’s disease. Molecular Neurobiology;45(1):87-98, 2012.
M Guan, R Liu, K Lam, J Lou, J Nolta, B Panganiban, R Ritchie, N Lane, W Yao. Directing mesenchymal stem cells
to bone to increase bone formation. Nature Medicine;18(3):456-62, 2012.
Books, Invited Articles, and Chapters (Selected, 3 of 22)
16. Meyerrose TM, Herrbrich P, Wang X, Dao MA, Nolta JA. Pluripotent human stem cell analysis in immune deficient mice. The
Pluripotential Hematopoietic Stem Cell, Editor: J. Keller. Eurekah Press, 2003.
17. Meyerrose TE, Herrbrich P, Hess DA, Nolta JA. Immune-deficient mouse models for analysis of human stem cells.
Biotechniques. Dec; 35 (6):1262-72, 2003.
18. Meyerrose T, Rosova I, Dao M, Bauer G, and Nolta JA. Establishment and transduction of primary human mesenchymal stem
cell monolayers. Chapter 2 in Genetic Engineering of Mesenchymal Stem Cells. Kluwer, pp 45-58. Nolta JA (Editor). Feb 2006.
19. FA. Fierro, J Egana, C Toupadakis, C Yellowley, H Machens, JA Nolta. Small Animal models of tissue regeneration. Chapter 20
in Stem Cell Biology and Regenerative Medicine. H. Bernstein (Editor), 2011.
20. Armstrong L, Lako M, Buckley N, Lappin TR, Murphy MJ, Nolta JA, Pittenger M, Stojkovic M. Our top 10 developments in
stem cell biology over the last 30 years. Stem Cells. Jan; 30(1):2-9, 2012.
21. G Annett, G Bauer and J Nolta. Mesenchymal Stem Cells for Trinucleotide Repeat Disorders. In press, Trinucleotide Repeat
Protocols, Second Edition, edited by Kohwi and McMurray, 2012.
Relevant Investigator-initiated INDs/Clinical Trials (blue-NIH-RAC numbers for gene therapy trials, Nolta sub-investigator):
0301-566 Infusion of Genetically Modified T cells: Tracking and Toxicity (DiPersio)
0602-758 Lentiviral-Mediated Gene Therapy for MPS VII (Sands)
9306-047 Retroviral Mediated Transfer of the cDNA for Human GC into Stem Cells of Patients with Gaucher Disease. (Kohn)
9908-337 Transduction of CD34+ Cells from Children with Adenosine Deaminase (ADA)-Deficient SCID (Kohn)
NCT00871702: Infusion of Genetically Modified T Cells for Post-Transplant Patients with Relapsed Disease (DiPersio)
FDA IND: BB IND# 13065. Stem Cell Implantation in Elderly Patients Undergoing CABG (Rich)
FDA IND: BB IND# 14848. Infusion of autologous cord blood for traumatic brain injury
FDA IND: BB IND# 13307. Autologous Bone Marrow Derived CD34+ Cells Selected with Magnetic-activated Cell Sorter
(CliniMACS, Miltenyi); Intravitreal Injection (Park).
Patent Applications/Patents
- Mesenchymal Stem Cells producing inhibitory RNA for disease modification. ROI 2008. UC Patent 2009-170-1; Ref.:
060933-4300. Inventors: Scott Olson, Ph.D., Louisa Wirthlin, B.S., Jan Nolta Ph.D. International Filing 2009.
- Combination anti-HIV vectors, targeting vectors, and methods of use. PCT/US2010033042. Inventors J. Anderson, G.
Bauer, Jan Nolta, 2009.
- EIIIA and EIIIB segments of fibronectin regulate stem cell fate. 060933-5650. S.Pontow, J.Peters Jan Nolta. 2010.
- HIV resistant immune system cells from induced pluripotent stem cells. J. Anderson, G. Bauer, Jan Nolta, ROI 2010
- Decellularized liver matrix and iPSC-derived hepatocytes for liver bioengineering. J. Wu, P. Zhou, J Nolta, ROI 2010.
Research Projects - Active:
1) 1R01GM099688-01 (Nolta) 07/01/2011 - 06/30/2016
$2,700,217 total
1.8 months effort
NIH Common fund transformative research projects program
Direct cell to cell transfer of microRNA for tissue repair. The studies will examine the use of human mesenchymal
stem cells to deliver microRNA and other key factors to damaged tissues to hasten repair.
2) TR1-01257: CIRM (Nolta)
08/01/09-07/31/12
$2,753,559 total
3.0 months (25%) Effort
Sustained siRNA production from human MSC to treat Huntington’s disease and other neurodegenerative
disorders. The goal is to develop a novel MSC-based strategy for stem cell therapy to treat Huntington's disease, leading
toward clinical trials.
3) 1RO1 HL073256-01 (Nolta) NIH NHLBI 07/01/03 - 06/30/12 $250,000 DC/yr
1.8 months (15%) Effort
Functional Dissection of human adipose-derived MSC and bone marrow-derived MSC phenotypes. The goal is to
identify the most primitive subsets of primary human MSC and to determine the functional differentiative potential of
each defined subset and the homing and tissue regenerative potential in immune deficient mice.
4) TR2-01787: CIRM (Isseroff PI, Nolta Co-PI)
02/01/11-01/31/14 $4,526,900 total
1.8 months (15%)
Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds
The goal of the proposed studies is to move a development candidate composite stem cell/ decellularized matrix construct
to the clinic for non-healing ulcers in diabetic patients seen in Dr. Isseroff’s wound care clinic at the VA hospital
5) 2P51RR000169-49. Stem Cell Therapies for Huntington’s disease 2011-2012
To conduct IND-enabling studies with the UC Davis CTSC in support of a stem cell clinical trial for HD
6) 2RO1DK61848 (Nolta), NIH NIDDK
09/30/01 – 06/30/11
$250,000 DC/ yr.
NCE
Immunodeficient mouse model of stem cell plasticity. The goal of the proposed studies is to develop immune deficient
mouse models in which the origin of blood and liver cells can be traced to a common stem cell precursor and can be
rigorously demonstrated by the single cell clonal integration analysis techniques developed in the Nolta lab.
7) TR2-01857: CIRM (Zern PI, Nolta Co-Investigator) 2011-2013 $1,271,316/yr
1.2 months (10%) effort
Liver Cell Transplantation
The goal is to establish human embryonic stem cells as a source of hepatocytes for therapy of patients with liver failure.
8) 5RC1AG036022-02: ARRA Challenge grant (Hagerman PI, Nolta, Pesseh co-Is).
0.96 months (8%)
10/2009 -09/2011
$999,924.00
Human iPSC neuronal models for FXTAS neurodegeneration
The goal of the study is to generate induced pluripotent stem cells from the fibroblast cell lines from the consented
FXTAS patients seen by the Hagermans and to study the potential signaling deficits from neurons derived from each
pluripotent cell line, in comparison to unaffected controls.
9) TB1-01184: CIRM (Trainer, Jill PI, Nolta Co-PI)
10/01/09 – 09/31/12
0.48 months (4%)
Bridges to Stem Cell Research Training Program. Bridges is an innovative collaborative program between California
State University Sacramento (CSUS) and UC Davis to train state college Master’s Program interns in the practical aspects
of stem cell biology, good manufacturing practices, good laboratory practices, and Cellular therapy. Subcontract amount
varies with student # trained in the UC Davis Stem Cell Program each year.
10) RN1-00561: CIRM (Chong Pan PI, Nolta Co-mentor)
2008-2013 $300,000 DC/yr
0.6 months (5%)
Combinatorial Chemistry Approaches to Develop Ligands against Leukemia Stem Cells. Dr. Nolta is the stem cell
mentor for Dr. Pan’s junior faculty grant, along with Dr. Kit Lam for the chemistry portion.
11) RM1-01724: CIRM (Murphy PI, Nolta co-investigator) 2010-2013 $154,807/yr
1.2 months (10%) effort
Natural killer (NK) cells as “veto” cells to promote donor-specific tolerance. Develop methods to tolerize recipients
to engrafted tissues by the use of donor NK cells.
12) RB2-01567: CIRM (Kurzrock PI, Nolta co-PI)
2010-2013 $ 441,360/yr DC
0.6 months (5%)
Differentiation of Human Embryonic Stem Cells into Urothelium. The goal is to develop bladder tissue replacement
constructs for patients with cancer and spin bifida, both causing loss or absence of functional bladder tissue.
Pending grants:
CIRM DR2A-05415 "MSC engineered to produce BDNF for the treatment of Huntington's disease", PI Vicki Wheelock,
MD, Co-PI Jan Nolta, PhD 9/1/12 -8/31/16 Total: $ 18,950,059
CIRM DR2A-05423 "Phase I study of IM Injection of VEGF Producing MSC for the Treatment of Critical Limb
Ischemia", PI John Laird, MD, Co-PI Jan Nolta, PhD Total: $ 14,184,594
Previous Grants
12) CIRM FA-00611-1: Institutional grant: Nolta, designated contact,
$20,083,000
CIRM Major Facilities Grant: this award was for “Bricks and Mortar” and equipment for renovation of the new UC
Davis/CIRM Institute for Regenerative Cures, which is now the hub for the rapidly growing UC Davis stem cell program
(currently over 150 faculty members).
13) 1S10RR026825-01 (Nolta) NIH NCRR
01/26/10
$499,785
Shared LSRII Cytometer Equipment Application – this award funded a shared cytometer for the Stem Cell Program’s
Sorter Core in the new Institute for Regenerative Cures.
14) 5P30AG010129 - 19 (DeCarli, PI, Nolta - Pilot grant PI)
10/09-09/10
$34,000
The goal of this pilot project on Dr. DeCarli’s center grant was for Dr. Nolta to mentor Dr. Olson in her lab, who will
investigate the use of human MSC to deliver biotherapeutics for Alzheimer’s disease directly into the brain tissue.
15) 1R01HL073762-01 (Link),
NIH NHLBI
07/01/03 – 06/30/07
$250,000 DC/yr
Stem Cell Mobilization to enhance tissue repair. Regimens to mobilize murine hematopoietic, mesenchymal, and
endothelial progenitors capable of mediating repair of damaged cardiac tissue were determined.
16) 2R01DK53041 (Nolta), NIH NIDDK
09/30/97 - 04/30/07
$250,000 DC/yr
Ex-vivo Stem Cell Manipulation and Human Hematopoiesis. The goal was to promote primitive human hematopoietic
progenitor survival and self-renewal in vitro, and to determine molecular changes that precede lineage commitment in
human stem cells.
17) HL54850-02 (Nolta), NIH NHLBI
1/1/01 - 12/31/06
$242,000 DC/yr
Specialized Center of Research (Parkman), Project 2 (Nolta); In vivo model for human stem cells. The goal of this
project was to examine transduction, in vivo differentiation, and the molecular aspects of cell cycle regulation in human
hematopoietic stem cells.
18) 1R21DK62892-01 (Nolta) NIH NIDDK
03/01/03 – 02/28/06
$100,000 DC/ yr.
HGF (Hepatocyte growth factor) induces robust human thymopoiesis in mice
The goal was to produce better xenograft models in which to examine human T cell reactivity. The models are now used
by the UC Davis HIV team researchers.